CTSB and central nervous system cancer: According to the clinical meaning of these molecular phenotypes in gliomas, patients with highly-expressed CTSB may have a greater risk of tumor recurrence, progression, epithelial mesenchymal transformation (EMT) and therapeutic resistance.